Colorectal News and Research

RSS

Scientists identify novel gene mutation that causes glioblastoma

Scientists at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center, in collaboration with colleagues in Boston and South Korea, say they have identified a novel gene mutation that causes at least one form of glioblastoma (GBM), the most common type of malignant brain tumor.

18 Nov 2011

China Medical Technologies second quarter net revenues increase 18.1% to RMB238.5 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, announced its unaudited financial results for the second fiscal quarter ended September 30, 2011 ("2Q FY2011") today.

18 Nov 2011

Complications from preventable surgical-site infections leading to hospital readmissions after colon surgery

Nearly one-quarter of privately insured colon surgery patients are readmitted to the hospital within three months of discharge at a cost of roughly $9,000 per readmission, according to Johns Hopkins researchers, who've identified a major area for quality improvement and cost reduction in health care.

17 Nov 2011

VHIO, MGHCC sign tumor biomarker agreement

The President of the BBVA Foundation, Francisco Gonz-lez, Jose Baselga, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center (MGHCC), and Andr-s de Kelety, Managing Director at the Vall d'Hebr-n Institute of Oncology (VHIO) in Barcelona, yesterday signed the agreement creating the BBVA Foundation Tumor Biomarkers Research Program.

17 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Malpractice lawsuits linked to surgeon depression and career burnout

According to the results of a new study published in the November 2011 Journal of the American College of Surgeons, malpractice lawsuits against U.S. surgeons occur often and can take a profound personal toll on the surgeon, resulting in emotional exhaustion, stress, and professional dissatisfaction.

15 Nov 2011

Women with inflammatory breast cancer now have a chance of treatment

Women with the deadliest and rarest form of breast cancer now have a chance of treatment where once their options were severely limited, thanks to a new discovery by George Mason University researchers.

15 Nov 2011

Fiber from whole grains reduces risk of bowel cancer: Study

The researchers from Britain and the Netherlands found that the more total dietary fiber and cereal fiber people consumed, the lower their colorectal cancer risk. For example, people who consumed an extra 90 grams of fiber from whole grains a day also had a 20 percent lower risk of colorectal cancer, according to the British Medical Journal review.

14 Nov 2011

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

14 Nov 2011

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

11 Nov 2011

JMC launches comprehensive lung cancer program

Recruiting one of the nation's leading specialists in minimally-invasive lung and chest surgery, Jupiter Medical Center (JMC) has launched the first comprehensive program in Palm Beach and Martin counties dedicated to prevention, early detection, treatment and care of patients with lung cancer and other diseases of the chest and lung.

10 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Researchers plan joint clinical trials of new cancer treatments, personalized therapies

The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.

9 Nov 2011

FOBt-based colorectal cancer screening programme cuts death rate by 27%

Bowel screening reduces the number of deaths from bowel cancer in Scotland by more than 25 per cent, according to research* presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool this week.

9 Nov 2011

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

8 Nov 2011

New breast and ovarian cancer vaccine in the pipeline: Study

A new vaccine is being tried clinically to combat tumor cells in a small study of advanced breast and ovarian cancer patients. The results show that there is improvement in overall survival times and stopping the disease for a handful of breast cancer patients.

8 Nov 2011

Transgenomic and A. Menarini Diagnostics enter distribution agreement for mutation detection systems

Transgenomic, Inc. and A. Menarini Diagnostics today announced an exclusive distribution agreement for Transgenomic's SURVEYOR Scan and WAVE MCE (Micro-Capillary Electrophoresis) Mutation Detection system to its network of over 2,000 pathologists throughout Europe.

7 Nov 2011

Colorectal News and Research

Scientists identify novel gene mutation that causes glioblastoma

China Medical Technologies second quarter net revenues increase 18.1% to RMB238.5 million

Complications from preventable surgical-site infections leading to hospital readmissions after colon surgery

VHIO, MGHCC sign tumor biomarker agreement

Amgen receives EC approval to extend therapeutic indications for Vectibix

Malpractice lawsuits linked to surgeon depression and career burnout

Women with inflammatory breast cancer now have a chance of treatment

Fiber from whole grains reduces risk of bowel cancer: Study

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

JMC launches comprehensive lung cancer program

Idera third quarter net loss increases to $5.5 million

Researchers plan joint clinical trials of new cancer treatments, personalized therapies

FOBt-based colorectal cancer screening programme cuts death rate by 27%

Salix enters definitive agreement to acquire Oceana Therapeutics

New breast and ovarian cancer vaccine in the pipeline: Study

Transgenomic and A. Menarini Diagnostics enter distribution agreement for mutation detection systems

Sleeping Beauty transposon system plays a vital role in investigating colorectal cancer pathway

SJH&MC the first in Southeast Michigan to offer Hyperthermic Intraperitoneal Chemotherapy

Study: Birth cohort screening for HCV is cost effective in primary care setting

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News